http://orcid.org/0000-0001-5093-6980
Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young & Nathorn Chaiyakunapruk. (2023) Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. Journal of Asthma 60:9, pages 1702-1714.
Read now
Read now
Javier Domínguez-Ortega, Daniel Laorden, Francisca Vílchez-Sánchez, David Bañas-Conejero & Santiago Quirce. (2023) Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting. Journal of Asthma 0:0, pages 1-9.
Read now
Read now
Sara Alves, João Cavaleiro Rufo & José Crispim. (2023) Economic evaluation of biological treatments in patients with severe asthma: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 23:7, pages 733-747.
Read now
Read now
Buendía Jefferson Antonio, Diana Guerrero Patiño & Melisa Lopez Moreno. (2022) Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 299-305.
Read now
Read now
Articles from other publishers (2)
Francesco Menzella, Carla Galeone, Giulia Ghidoni, Patrizia Ruggiero, Maria D'Amato, Matteo Fontana & Nicola Facciolongo. (2021) The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review. Multidisciplinary Respiratory Medicine 16.
Crossref
Crossref
A. Padilla-Galo, A. J. García-Ruiz, R. Ch. Levy Abitbol, C. Olveira, F. Rivas-Ruiz, N. García-Agua Soler, M. Pérez Morales, B. Valencia Azcona, B. Tortajada-Goitia, I. Moya-Carmona & A. Levy-Naon. (2021) Real-life cost-effectiveness of benralizumab in patients with severe asthma. Respiratory Research 22:1.
Crossref
Crossref